These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 9210683)
21. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. MacGowan AP; Bowker KE; Holt HA; Wootton M; Reeves DS J Antimicrob Chemother; 1997 Oct; 40(4):503-9. PubMed ID: 9372419 [TBL] [Abstract][Full Text] [Related]
22. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests. Barry AL; Fuchs PC; Brown SD Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):305-9. PubMed ID: 10385024 [TBL] [Abstract][Full Text] [Related]
23. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria. Aldridge KE Antimicrob Agents Chemother; 1994 Jul; 38(7):1671-4. PubMed ID: 7979307 [TBL] [Abstract][Full Text] [Related]
24. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Roblin PM; Hammerschlag MR Antimicrob Agents Chemother; 1998 Apr; 42(4):951-2. PubMed ID: 9559818 [TBL] [Abstract][Full Text] [Related]
25. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Fass RJ Antimicrob Agents Chemother; 1997 Aug; 41(8):1818-24. PubMed ID: 9257770 [TBL] [Abstract][Full Text] [Related]
26. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Edmiston CE; Krepel CJ; Seabrook GR; Somberg LR; Nakeeb A; Cambria RA; Towne JB Antimicrob Agents Chemother; 2004 Mar; 48(3):1012-6. PubMed ID: 14982797 [TBL] [Abstract][Full Text] [Related]
27. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin. Klugman KP; Capper T J Antimicrob Chemother; 1997 Dec; 40(6):797-802. PubMed ID: 9462430 [TBL] [Abstract][Full Text] [Related]
28. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Brueggemann AB; Kugler KC; Doern GV Antimicrob Agents Chemother; 1997 Jul; 41(7):1594-7. PubMed ID: 9210692 [TBL] [Abstract][Full Text] [Related]
29. Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum. Stein GE; Schooley S; Tyrrell KL; Citron DM; Goldstein EJ Antimicrob Agents Chemother; 2003 Apr; 47(4):1308-12. PubMed ID: 12654663 [TBL] [Abstract][Full Text] [Related]
30. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria. Nord CE Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101 [TBL] [Abstract][Full Text] [Related]
31. Role of anaerobic bacteria in bite-wound infections. Goldstein EJ; Citron DM; Finegold SM Rev Infect Dis; 1984; 6 Suppl 1():S177-83. PubMed ID: 6372026 [TBL] [Abstract][Full Text] [Related]
32. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Ackermann G; Schaumann R; Pless B; Claros MC; Goldstein EJ; Rodloff AC Eur J Clin Microbiol Infect Dis; 2000 Mar; 19(3):228-32. PubMed ID: 10795599 [TBL] [Abstract][Full Text] [Related]
33. Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections. Nenoff P; Haustein UF; Hittel N Chemotherapy; 2004 Oct; 50(4):196-201. PubMed ID: 15452398 [TBL] [Abstract][Full Text] [Related]
34. In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species. Zhanel GG; Karlowsky JA; Hoban DJ Diagn Microbiol Infect Dis; 1998 Jun; 31(2):343-7. PubMed ID: 9635908 [TBL] [Abstract][Full Text] [Related]
35. In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobes. Biedenbach DJ; Jones RN Antimicrob Agents Chemother; 1995 Jul; 39(7):1636-42. PubMed ID: 7492122 [TBL] [Abstract][Full Text] [Related]
36. Comparative in vitro activities of amoxicillin-clavulanate against aerobic and anaerobic bacteria isolated from antral puncture specimens from patients with sinusitis. Goldstein EJ; Citron DM; Merriam CV Antimicrob Agents Chemother; 1999 Mar; 43(3):705-7. PubMed ID: 10049296 [TBL] [Abstract][Full Text] [Related]
37. [Bactericidal activity of Trovafloxacin and Moxifloxacin against Gram-negative anaerobic bacilli]. Bosnea D; Stadoleanu C; Boswell FJ; Buiuc D Rev Med Chir Soc Med Nat Iasi; 2000; 104(4):117-22. PubMed ID: 12089939 [TBL] [Abstract][Full Text] [Related]
38. In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas. Bébéar CM; Renaudin H; Boudjadja A; Bébéar C Antimicrob Agents Chemother; 1998 Mar; 42(3):703-4. PubMed ID: 9517957 [TBL] [Abstract][Full Text] [Related]
39. In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates. Molitoris D; Väisänen ML; Bolaños M; Finegold SM Antimicrob Agents Chemother; 2006 May; 50(5):1887-9. PubMed ID: 16641470 [TBL] [Abstract][Full Text] [Related]
40. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]